Business Wire

CIRIUM

Share
New Cirium Airline Finance Rankings Show an Industry Net Loss of Nearly $220 Billion Since the Pandemic Began

Cirium’s analysis of the World Airline Group Finance Rankings results for 2021 and the first half of 2022, shows how the steep decline in airline revenues has translated into a net loss of nearly $220 billion over the past two and a half years since the pandemic began.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221201005382/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Cirium airline group corporate financial results for the first half of 2022. (Photo: Business Wire)

The full extent of damage from the pandemic shows through in the latest Cirium airline rankings. Revenues for the world’s airline groups more than halved in 2020 and, despite some recovery, ended 2021 still down by over 40% on pre-pandemic levels. At $500 billion, revenues remain lower than they were 15 years ago.

With most airline financial results in for the first half of 2022, there are further signs of recovery from the depth of the crisis, but the industry is expected to show another loss for the whole of 2022.

Jeremy Bowen, CEO at Cirium said: “It’s a positive sign that the net deficit is decreasing year-over-year. In 2020, the revenue decline translated into net losses of $160 billion, another $42 billion last year and losses for the first half of this year total around $15 billion.

“If losses so far this year aren’t substantially added to, that would leave the airline industry with the overall net loss of nearly $220 billion since the start of 2020. However, if we assume that there are no further shocks to the industry, there is the possibility that the industry may break even in the second half of the year, led by US and European groups.”

Demand has been recovering, with global revenues up by 70% for the first six months of 2022, bringing the total to within 20% of 2019 levels.

Cirium’s World Airline Group Finance Rankings for the first half of 2022 shows strongest progress from the North American carriers as they marked up a 5% increase over pre-pandemic levels and returned to a modest operating profit.

Delta Air Lines returns to the top of the revenue ranking this year, with revenue virtually back to pre-pandemic levels. The Federal Express (FedEx) air cargo operation narrowly slips to second spot, having led throughout the pandemic thanks to a strong global air freight market, driven by surging demand for PPE and ecommerce.

Early results for the September quarter show the six largest US carriers now with record revenues and an overall net profit for the first nine months of the year, putting the industry on course to post a modest profit for the year if trends continue.

The major European airline groups such as Lufthansa, also showed strong recovery in first half revenues, following the lifting of travel restrictions in early 2022 which unleashed a wave of passenger demand.

Traffic within Western Europe has been running at around 95% of pre-pandemic levels since the middle of the year, raising revenues and returning the largest groups to profitability in the September quarter.

By contrast, the Asia-Pacific region has struggled, largely because of China’s continued COVID-19 lockdowns. Chinese airlines posted a 35% decline in revenue and a net loss of nearly $10 billion in the first half of 2022, higher than either of the previous two years. The results going into the second half of the year look likely to add to that deficit. That is likely to be offset to an extent by airlines within the rest of the region, but on current performance that looks unlikely to be enough to counter the deficit flowing from China.

Rank

 

Airline Group

 

Country

 

Revenue ($m)

 

Change (%)

 

Op Result

 

Operating Margin (%)

 

Net Result

 

Net Margin (%)

2022

 

2019

     

2022

 

22 v 21

 

22 v 19

 

2022

 

2022

 

2021

 

2020

 

2019

 

2022

 

2022

 

2021

 

2020

 

2019

1

 

1

 

Delta Air Lines

 

USA

 

23,172

 

105

%

 

1

%

 

736

 

3

%

 

-5

%

 

-52

%

 

14

%

 

-205

 

-1

%

 

-5

%

 

-62

%

 

9

%

2

 

5

 

FedEx

 

USA

 

23,072

 

8

%

 

23

%

 

1,599

 

7

%

 

7

%

 

2

%

 

6

%

 

1,402

 

6

%

 

7

%

 

3

%

 

6

%

3

 

2

 

American Airlines

 

USA

 

22,321

 

94

%

 

-1

%

 

-706

 

-3

%

 

-8

%

 

-50

%

 

7

%

 

-1,159

 

-5

%

 

-11

%

 

-42

%

 

4

%

4

 

3

 

United Airlines

 

USA

 

19,678

 

126

%

 

-6

%

 

-498

 

-3

%

 

-19

%

 

-28

%

 

9

%

 

-1,048

 

-5

%

 

-21

%

 

-35

%

 

6

%

5

 

4

 

Lufthansa

 

Germany

 

16,107

 

108

%

 

-23

%

 

-215

 

-1

%

 

-29

%

 

-31

%

 

2

%

 

-353

 

-2

%

 

-28

%

 

-39

%

 

-1

%

If the industry does manage to contain its net loss for the full year around the $10-15 billion mark, it is worth remembering that is still equivalent to industry annual losses 20 years before in the wake of the crisis that followed the 9/11 attacks.

Cirium’s World Airline Group Passenger Rankings for 2021 and First Half of 2022 is a premium analysis available in Cirium Dashboard. The report features:

  • Top 25 airline groups by revenue ($m) Jan-Jun 2022
  • Top 100 airline groups by revenue ($m) 2021
  • Airline group corporate financial results by region Jan-Jun 2022 ($bn)
  • Passenger volumes by region Jan-Jun 2022
  • Airline group corporate financial results by region and airline type 2019-2021 ($bn)

Click here to download the full report.

Ends

About Cirium

Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.

For further information please follow Cirium updates on LinkedIn or Twitter or visit www.cirium.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221201005382/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 00:00:00 CET | Press release

Novel BCL2 inhibitor sonrotoclax monotherapy demonstrates deep and durable clinical responses in R/R MCL and R/R CLLSonrotoclax in combination with BRUKINSA demonstrated rapid MRD negativity in treatment-naive CLL, regardless of high-risk features BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemi

Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release

Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye